Remove Documentation Remove Information Remove Packaging
article thumbnail

Gerresheimer enhances pharma packaging registration with comprehensive product database

Express Pharma

Gerresheimer, a systems and solutions provider for the pharmaceutical and biotech industry, has introduced a web-based product database designed to streamline the selection and registration of primary plastic packaging for medicinal products. It contains revision dates, test results, certifications, and regulatory documentation.

article thumbnail

More on the Impact of the FDA RIFs: How Information Disclosure will Start FOIA-lling Behind

FDA Law Blog: Biosimilars

While much of the focus has been on how these cuts may impact application review timelines and industry engagement, see earlier post about the effect on generic drugs, another quieter consequence is emerging a significant slowdown in the availability of information that FDA is required to produce under the Freedom of Information Act (FOIA).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New biosimilar pathways – key takeaways from the EMA’s draft reflection paper

European Pharmaceutical Review

Advances in analytical science, combined with the EMA’s regulatory experience, have shown that CES often do not provide additional meaningful information when the biosimilar and RMP are already well-characterised. Document 9286/25. Brussels: Council of the European Union; 2 June 2025. Interinstitutional File: 2023/0131 (COD).

article thumbnail

Pharmacy Law and Licensing Highlights 2025

FDA Law Blog: Biosimilars

The rules were implemented to enhance patient safety protections via revised drug handling, packaging, and delivery requirements. The rules include changes to the notification process, medication packaging, the handling of reports, and safety issues. Hyman, Phelps & McNamara, P.Cs

article thumbnail

FDA guidance highlights E&L considerations for ophthalmic drug products

European Pharmaceutical Review

This document is revised from a version published in October 2023. Firstly, leachables can compromise a products quality and therapeutic effect, by potentially interacting with the formulated drug product, the document reported. Moreover, manufacturers should document information about their safety thresholds, the guidance stated.

article thumbnail

Addressing US FDA challenges in Indian sterile drug manufacturing – Part 2

Express Pharma

Rising expectations for scientific rationale One consistent theme across FDA communications, including 483s, Warning Letters, and guidance documents is the demand for sound scientific justification behind design and operational decisions. Interventions were neither documented nor risk-assessed.

article thumbnail

Development and Manufacturing of Primary Packaging and Medical Devices

Pharmaceutical Technology

Packaging plays a critical part in the pharmaceuticals and medical devices industries and is developed with its own set of security standards for the safety of consumers. The role of primary packaging has extended beyond the primary objectives of sterility, physical and chemical protection, and security.